Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients

Wen Pin Su, Chi Chung Wen, Chao A. Hsiung, Ih Jen Su, Ann Lii Cheng, Ming Chih Chang, Chao Jung Tsao, Woei Yao Kao, Wu Ching Uen, Chih Hung Hsu, Yen Shen Lu, Hwei Fan Tien, Tsu Yi Chao, Li Tzong Chen, Jacqueline Whang-Peng, Pei Jer Chen

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Aim: To investigate the long-term consequences of chemotherapy-related HBV reactivation in patients with lymphoma. Methods: This study was based on the database of published prospective study evaluating HBV reactivation in HBV lymphoma patients during chemotherapy. Deteriorated liver reserve (DLR) was defined as development of either one of the following conditions during follow-up: (1) newly onset parenchyma liver disease, splenomegaly or ascites without evidence of lymphoma involvement; (2) decrease of the ratio (albumin/globulin ratio) to less than 0.8 or increase of the ratio of INR of prothrombin time to larger than 1.2 without evidence of malnutrition or infection. Liver cirrhosis was diagnosed by imaging studies. Results: A total of 49 patients were included. The median follow-up was 6.2 years (range, 3.9-8.1 years). There were 31 patients with and 18 patients without HBV reactivation. Although there was no difference of overall survival (OS) and chemotherapy response rate between the two groups, DLR developed more frequently in patients with HBV reactivation (48.4% vs 16.7%; P = 0.0342). Among the HBV reactivators, HBV genotype C was associated with a higher risk of developing DLR (P = 0.0768) and liver cirrhosis (P = 0.003). Four of five patients with sustained high titer of HBV DNA and two of three patients with multiple HBV reactivation developed DLR. Further, patients with a sustained high titer of HBV DNA had the shortest OS among the HBV reactivators (P = 0.0000). No patients in the non-HBV reactivation group developed hepatic failure or liver cirrhosis. Conclusion: Chemotherapy-related HBV reactivation is associated with the long-term effect of deterioration of hepatic function.

Original languageEnglish
Pages (from-to)5283-5288
Number of pages6
JournalWorld Journal of Gastroenterology
Volume11
Issue number34
Publication statusPublished - Sep 14 2005
Externally publishedYes

Fingerprint

Lymphoma
Drug Therapy
Liver
Liver Cirrhosis
International Normalized Ratio
Survival
DNA
Prothrombin Time
Splenomegaly
Globulins
Liver Failure
Ascites
Malnutrition
Liver Diseases
Albumins
Genotype
Databases
Prospective Studies
Infection

Keywords

  • Chemotherapy
  • HBV reactivation
  • Liver function
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Su, W. P., Wen, C. C., Hsiung, C. A., Su, I. J., Cheng, A. L., Chang, M. C., ... Chen, P. J. (2005). Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. World Journal of Gastroenterology, 11(34), 5283-5288.

Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. / Su, Wen Pin; Wen, Chi Chung; Hsiung, Chao A.; Su, Ih Jen; Cheng, Ann Lii; Chang, Ming Chih; Tsao, Chao Jung; Kao, Woei Yao; Uen, Wu Ching; Hsu, Chih Hung; Lu, Yen Shen; Tien, Hwei Fan; Chao, Tsu Yi; Chen, Li Tzong; Whang-Peng, Jacqueline; Chen, Pei Jer.

In: World Journal of Gastroenterology, Vol. 11, No. 34, 14.09.2005, p. 5283-5288.

Research output: Contribution to journalArticle

Su, WP, Wen, CC, Hsiung, CA, Su, IJ, Cheng, AL, Chang, MC, Tsao, CJ, Kao, WY, Uen, WC, Hsu, CH, Lu, YS, Tien, HF, Chao, TY, Chen, LT, Whang-Peng, J & Chen, PJ 2005, 'Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients', World Journal of Gastroenterology, vol. 11, no. 34, pp. 5283-5288.
Su WP, Wen CC, Hsiung CA, Su IJ, Cheng AL, Chang MC et al. Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. World Journal of Gastroenterology. 2005 Sep 14;11(34):5283-5288.
Su, Wen Pin ; Wen, Chi Chung ; Hsiung, Chao A. ; Su, Ih Jen ; Cheng, Ann Lii ; Chang, Ming Chih ; Tsao, Chao Jung ; Kao, Woei Yao ; Uen, Wu Ching ; Hsu, Chih Hung ; Lu, Yen Shen ; Tien, Hwei Fan ; Chao, Tsu Yi ; Chen, Li Tzong ; Whang-Peng, Jacqueline ; Chen, Pei Jer. / Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. In: World Journal of Gastroenterology. 2005 ; Vol. 11, No. 34. pp. 5283-5288.
@article{444459a8266644c3bb7c28596678956f,
title = "Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients",
abstract = "Aim: To investigate the long-term consequences of chemotherapy-related HBV reactivation in patients with lymphoma. Methods: This study was based on the database of published prospective study evaluating HBV reactivation in HBV lymphoma patients during chemotherapy. Deteriorated liver reserve (DLR) was defined as development of either one of the following conditions during follow-up: (1) newly onset parenchyma liver disease, splenomegaly or ascites without evidence of lymphoma involvement; (2) decrease of the ratio (albumin/globulin ratio) to less than 0.8 or increase of the ratio of INR of prothrombin time to larger than 1.2 without evidence of malnutrition or infection. Liver cirrhosis was diagnosed by imaging studies. Results: A total of 49 patients were included. The median follow-up was 6.2 years (range, 3.9-8.1 years). There were 31 patients with and 18 patients without HBV reactivation. Although there was no difference of overall survival (OS) and chemotherapy response rate between the two groups, DLR developed more frequently in patients with HBV reactivation (48.4{\%} vs 16.7{\%}; P = 0.0342). Among the HBV reactivators, HBV genotype C was associated with a higher risk of developing DLR (P = 0.0768) and liver cirrhosis (P = 0.003). Four of five patients with sustained high titer of HBV DNA and two of three patients with multiple HBV reactivation developed DLR. Further, patients with a sustained high titer of HBV DNA had the shortest OS among the HBV reactivators (P = 0.0000). No patients in the non-HBV reactivation group developed hepatic failure or liver cirrhosis. Conclusion: Chemotherapy-related HBV reactivation is associated with the long-term effect of deterioration of hepatic function.",
keywords = "Chemotherapy, HBV reactivation, Liver function, Non-Hodgkin's lymphoma",
author = "Su, {Wen Pin} and Wen, {Chi Chung} and Hsiung, {Chao A.} and Su, {Ih Jen} and Cheng, {Ann Lii} and Chang, {Ming Chih} and Tsao, {Chao Jung} and Kao, {Woei Yao} and Uen, {Wu Ching} and Hsu, {Chih Hung} and Lu, {Yen Shen} and Tien, {Hwei Fan} and Chao, {Tsu Yi} and Chen, {Li Tzong} and Jacqueline Whang-Peng and Chen, {Pei Jer}",
year = "2005",
month = "9",
day = "14",
language = "English",
volume = "11",
pages = "5283--5288",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "34",

}

TY - JOUR

T1 - Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients

AU - Su, Wen Pin

AU - Wen, Chi Chung

AU - Hsiung, Chao A.

AU - Su, Ih Jen

AU - Cheng, Ann Lii

AU - Chang, Ming Chih

AU - Tsao, Chao Jung

AU - Kao, Woei Yao

AU - Uen, Wu Ching

AU - Hsu, Chih Hung

AU - Lu, Yen Shen

AU - Tien, Hwei Fan

AU - Chao, Tsu Yi

AU - Chen, Li Tzong

AU - Whang-Peng, Jacqueline

AU - Chen, Pei Jer

PY - 2005/9/14

Y1 - 2005/9/14

N2 - Aim: To investigate the long-term consequences of chemotherapy-related HBV reactivation in patients with lymphoma. Methods: This study was based on the database of published prospective study evaluating HBV reactivation in HBV lymphoma patients during chemotherapy. Deteriorated liver reserve (DLR) was defined as development of either one of the following conditions during follow-up: (1) newly onset parenchyma liver disease, splenomegaly or ascites without evidence of lymphoma involvement; (2) decrease of the ratio (albumin/globulin ratio) to less than 0.8 or increase of the ratio of INR of prothrombin time to larger than 1.2 without evidence of malnutrition or infection. Liver cirrhosis was diagnosed by imaging studies. Results: A total of 49 patients were included. The median follow-up was 6.2 years (range, 3.9-8.1 years). There were 31 patients with and 18 patients without HBV reactivation. Although there was no difference of overall survival (OS) and chemotherapy response rate between the two groups, DLR developed more frequently in patients with HBV reactivation (48.4% vs 16.7%; P = 0.0342). Among the HBV reactivators, HBV genotype C was associated with a higher risk of developing DLR (P = 0.0768) and liver cirrhosis (P = 0.003). Four of five patients with sustained high titer of HBV DNA and two of three patients with multiple HBV reactivation developed DLR. Further, patients with a sustained high titer of HBV DNA had the shortest OS among the HBV reactivators (P = 0.0000). No patients in the non-HBV reactivation group developed hepatic failure or liver cirrhosis. Conclusion: Chemotherapy-related HBV reactivation is associated with the long-term effect of deterioration of hepatic function.

AB - Aim: To investigate the long-term consequences of chemotherapy-related HBV reactivation in patients with lymphoma. Methods: This study was based on the database of published prospective study evaluating HBV reactivation in HBV lymphoma patients during chemotherapy. Deteriorated liver reserve (DLR) was defined as development of either one of the following conditions during follow-up: (1) newly onset parenchyma liver disease, splenomegaly or ascites without evidence of lymphoma involvement; (2) decrease of the ratio (albumin/globulin ratio) to less than 0.8 or increase of the ratio of INR of prothrombin time to larger than 1.2 without evidence of malnutrition or infection. Liver cirrhosis was diagnosed by imaging studies. Results: A total of 49 patients were included. The median follow-up was 6.2 years (range, 3.9-8.1 years). There were 31 patients with and 18 patients without HBV reactivation. Although there was no difference of overall survival (OS) and chemotherapy response rate between the two groups, DLR developed more frequently in patients with HBV reactivation (48.4% vs 16.7%; P = 0.0342). Among the HBV reactivators, HBV genotype C was associated with a higher risk of developing DLR (P = 0.0768) and liver cirrhosis (P = 0.003). Four of five patients with sustained high titer of HBV DNA and two of three patients with multiple HBV reactivation developed DLR. Further, patients with a sustained high titer of HBV DNA had the shortest OS among the HBV reactivators (P = 0.0000). No patients in the non-HBV reactivation group developed hepatic failure or liver cirrhosis. Conclusion: Chemotherapy-related HBV reactivation is associated with the long-term effect of deterioration of hepatic function.

KW - Chemotherapy

KW - HBV reactivation

KW - Liver function

KW - Non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84983718388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983718388&partnerID=8YFLogxK

M3 - Article

C2 - 16149133

AN - SCOPUS:84983718388

VL - 11

SP - 5283

EP - 5288

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 34

ER -